January 20, 2022 News by Lindsey Shapiro, PhD Cyxone to Scale Up Production of T20K, Plant-derived Therapy for MS Cyxone will work with a European organization to scale up production of the active ingredient in T20K, its experimental treatment for multiple sclerosis (MS), the company announced. The collaboration, which will cover the development of a new manufacturing method and later the…
October 28, 2021 News by Patricia Inacio, PhD T20K Combo Shows Promise in MS Preclinical Studies New preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS). In a collaboration with its academic partner, the Medical University of Vienna, Cyxone has shown that a combination of T20K plus an activator of the kappa…
November 3, 2020 News by Joana Carvalho, PhD Beetroot Peptide May Hold Promise in Treating MS, Similar Diseases A small protein isolated from beetroot is able to block the activity of an enzyme called prolyl oligopeptidase (POP), which breaks down certain hormones and signaling molecules, and is thought to control the body’s inflammatory responses. According to the researchers, the discovery of this plant-derived protein may make possible…
August 6, 2019 News by Marta Figueiredo, PhD Phase 1 Study Finds T20K, Plant Protein-derived Compound for MS, Safe and Tolerable, Cyxone Says A Phase 1 clinical trial found T20K, Cyxone’s investigational plant protein-derived treatment for multiple sclerosis (MS), to be safe and well-tolerated in healthy men, and raising the possibility that it might work at low doses, the company announced. A next step is to develop an oral formulation for the…
July 17, 2019 News by Joana Carvalho, PhD Phase 1 Trial of T20K, Plant Protein-derived Therapy for MS, Doses 1st Group of Healthy Men A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis (MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational…
June 21, 2019 News by Joana Carvalho, PhD Cyxone Launches Phase 1 Trial Assessing T20K for MS Cyxone launched the first-in-human Phase 1 clinical trial assessing the effects of T20K, its new therapeutic candidate for the treatment of multiple sclerosis (MS), in healthy volunteers. The announcement came after the company received approval from the Dutch Ethics Committee and Central Commission on Research Involving Human…
May 31, 2019 News by Ana Pena PhD Cyxone Nears First-in-human Trial for Investigational Preventive MS Treatment T20K Cyxone submitted an application to the Netherlands research ethics committee to start the first clinical trial in humans testing T20K, its investigational preventive treatment for multiple sclerosis (MS). Approval by the Netherlands regulating authority…
March 26, 2019 News by Joana Carvalho, PhD T20K in Good Position to Become Preventive MS Treatment, Cyxone Says T20K, Cyxone‘s lead compound for treating multiple sclerosis (MS), seems able to prevent or slow disease progression, according to data from preclinical studies. Based on these findings, the company is confident that T20K might become a prophylactic (preventive) medication for MS in the near future. T20K is a…
